The two companies plan to design a 400G-per-lane thin-film lithium niobate (TFLN) modulator-based engine. ・POET Technologies’ ...
Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathologySYX-5219 is a ...
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator ...
InvestorsHub on MSN
POET Technologies Shares Climb on New AI-Focused Partnership with QCi
POET Technologies Inc. (NASDAQ:POET) shares rose 2.3% in premarket trading Tuesday after the company announced a strategic ...
Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027Hosted key opinion leader event highlighting ...
As Neuphoria Therapeutics considers its options in the wake of the failure of its phase 3 social anxiety program, an ...
US biotech Dewpoint Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator for the ...
These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes ...
Swave Photonics, the true holographic display company, today announced that its Holographic eXtended Reality (HXR) Spatial ...
The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback